Sermorelin

Potential Benefits of Sermorelin

• Promotes healthy muscles and bones [1-5]
• Lowers the risk of heart disease [6-8]
• Boosts immunity [9-11]
• Lowers blood pressure [12-15]
• Helps lose weight [16-19]
• Promotes wound healing [20-24]
• Improves brain health [25-26]

What is Sermorelin?

Sermorelin acetate, also known as sermorelin, is a growth hormone-releasing hormone (GHRH). It is mainly used for the treatment of growth hormone deficiency in children. It is also used for the evaluation of pituitary function. Insufficiency of GHRH can impair growth and lead to various health issues. Sermorelin exerts its health benefits by boosting the production of growth hormone in the body.

How Sermorelin Works?

Sermorelin stimulates the pituitary gland to increase the production of growth hormone (GH) and, subsequently, the level of insulin-like growth factor 1 (IGF-1). This in turn contributes to muscle growth, fat loss, bone repair, and improved wound healing.

Chemical Structure of Sermorelin

Research on Sermorelin

Promotes Healthy Muscles and Bones

Studies show that sermorelin is vital for muscle and bone health:

1. A study showed that sermorelin treatment resulted in increased lean body mass. [1]
2. In healthy adult men, sermorelin therapy improved the muscle strength on the lower part of the body. [2]
3. A study found that GH deficiency was associated with increased risk of osteoporosis, suggesting that boosting GH levels with sermorelin may have a positive effect. [3]
4. A study showed that GH deficiency inhibits bone growth and increases the risk of bone complications. [4]
5. In GH-deficient children, daily administration of sermorelin was found to be effective in increasing the height of the subjects. [5]

Lowers the Risk of Heart Disease

Sermorelin has also been shown to protect against heart disease:

1. In rats that suffered from heart attack, sermorelin treatment promoted recovery by reducing the inflammatory response. [6]
2. A study showed that sermorelin treatment improved blood flow to the heart. [7]
3. A study has shown that treatment with sermorelin produced therapeutic effects on the heart’s function and performance after a heart attack. [8]

Boosts Immunity

Evidence also supports the immune-boosting properties of sermorelin:

1. In rodents, the administration of sermorelin significantly improved the production of immune system cells. [9]
2. In aging individuals, the supplementation of sermorelin showed great immune-enhancing benefits. [10]
3. In burned mice infected with herpes, daily administration of sermorelin profoundly increased the survival rate of the subjects. [11]

Lowers Blood Pressure

Studies show that sermorelin has anti-hypertensive properties:

1. In rats, the administration of sermorelin produced blood pressure-lowering effects. [12]
2. A number of studies suggest that sermorelin lowers blood pressure by reducing resistance within the blood vessels and improving blood circulation. [13-15]

Helps Lose Weight

Sermorelin can also help reduce body fat mass and improve body composition:

1. In obese adults, weekly administration of sermorelin resulted in a significant reduction in abdominal fat. [16]
2. In obese patients, sermorelin supplementation accelerated body fat loss, especially in the abdominal area. [17]
3. In older adults, the supplementation of sermorelin demonstrated consistency in improving body composition. [18]
4. In rats with fatty liver, treatment with sermorelin reduced weight and fat accumulation. [19]

Promotes Wound Healing

Studies suggest that the GH-boosting effects of sermorelin can help speed up the wound healing process:

1. A study showed that topical application of GHRH resulted in shorter and better wound healing. [20]
2. A review of studies showed that GH deficiency was associated with poor wound healing. [21]
3. In mice, the application of GH-containing collagen film improved wound healing. [22]
4. In a mouse model of pressure ulcer, skin application of sermorelin accelerated the wound healing in the subjects. [23]
5. A study showed that sermorelin promoted the healing and repair of wounded tissues in the skin. [24]

Improves Brain Health

Sermorelin can also play a role in improving cognitive function:

1. In healthy adults and adults with mild cognitive impairment, sermorelin administration improved learning, memory, and other brain functions. [25]
2. In patients with traumatic brain injury (TBI), sermorelin therapy was shown to be effective in treating TBI-associated cognitive dysfunction. [26]

Associated Side Effects of Sermorelin

Sermorelin side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on sermorelin. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of sermorelin. Despite this, it was listed as a side effect associated with sermorelin even though these associated side effects are very uncommon.

Side effects associated with sermorelin may include the following:

• Changes in taste
• Difficulty swallowing
• Dizziness
• Flushing
• Headache
• Hives
• Hyperactivity
• Nausea
• Pale skin
• Rash
• Sleepiness
• Tightness in the chest
• Vomiting

References

1. Lissett CA, Shalet SM. Effects of growth hormone on bone and muscle. Growth Horm IGF Res. 2000 Apr;10 Suppl B:S95-101. doi: 10.1016/s1096-6374(00)80018-0. PMID: 10984262.
2. Tavares AB, Micmacher E, Biesek S, et al. Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old. Int J Endocrinol. 2013;2013:942030. doi:10.1155/2013/942030.
3. Wüster C, Härle U, Rehn U, Müller C, Knauf K, Köppler D, Schwabe C, Ziegler R. Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis. Growth Horm IGF Res. 1998 Feb;8 Suppl A:87-94. doi: 10.1016/s1096-6374(98)80016-6. PMID: 10993598.
4. Olney RC. Regulation of bone mass by growth hormone. Med Pediatr Oncol. 2003 Sep;41(3):228-34. doi: 10.1002/mpo.10342. PMID: 12868124.
5. Thorner M, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group. J Clin Endocrinol Metab. 1996 Mar;81(3):1189-96. doi: 10.1210/jcem.81.3.8772599. PMID: 8772599.
6. Kanashiro-Takeuchi RM, Szalontay L, Schally AV, Takeuchi LM, Popovics P, Jaszberenyi M, Vidaurre I, Zarandi M, Cai RZ, Block NL, Hare JM, Rick FG. New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. Oncotarget. 2015;6(12):9728-39. doi: 10.18632/oncotarget.3303. PMID: 25797248; PMCID: PMC4496393.
7. Lombardi G, Colao A, Marzullo P, Ferone D, Longobardi S, Esposito V, Merola B. Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol. 1997 Oct;155 Suppl 1:S33-7; discussion S39. PMID: 9389993.
8. Kanashiro-Takeuchi RM, Takeuchi LM, Rick FG, Dulce R, Treuer AV, Florea V, Rodrigues CO, Paulino EC, Hatzistergos KE, Selem SM, Gonzalez DR, Block NL, Schally AV, Hare JM. Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):559-63. doi: 10.1073/pnas.1119203109. Epub 2011 Dec 27. PMID: 22203988; PMCID: PMC3258609.
9. Available at https://www.jci.org/articles/view/32830.
10. Khorram O, Yeung M, Vu L, Yen SS. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab. 1997 Nov;82(11):3590-6. doi: 10.1210/jcem.82.11.4363. PMID: 9360512.
11. Takagi K, Suzuki F, Barrow RE, Wolf SE, Kobayashi M, Herndon DN. Growth hormone improves immune function and survival in burned mice infected with herpes simplex virus type 1. J Surg Res. 1997 Apr;69(1):166-70. doi: 10.1006/jsre.1997.5066. PMID: 9202664.
12. Nyström HC, Klintland N, Caidahl K, Bergström G, Wickman A. Short-term administration of growth hormone (GH) lowers blood pressure by activating eNOS/nitric oxide (NO)-pathway in male hypophysectomized (Hx) rats. BMC Physiol. 2005;5:17. Published 2005 Nov 7. doi:10.1186/1472-6793-5-17.
13. Titterington JS, Sukhanov S, Higashi Y, Vaughn C, Bowers C, Delafontaine P. Growth hormone-releasing peptide-2 suppresses vascular oxidative stress in ApoE-/- mice but does not reduce atherosclerosis. Endocrinology. 2009;150(12):5478-5487. doi:10.1210/en.2009-0283.
14. Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997 Jan;46(1):89-96. doi: 10.1016/s0026-0495(97)90174-8. PMID: 9005976.
15. Weekers F, Van Herck E, Isgaard J, Van den Berghe G. Pretreatment with growth hormone-releasing peptide-2 directly protects against the diastolic dysfunction of myocardial stunning in an isolated, blood-perfused rabbit heart model. Endocrinology. 2000 Nov;141(11):3993-9. doi: 10.1210/endo.141.11.7768. PMID: 11089529.
16. Hong JW, Park JK, Lim CY, Kim SW, Chung YS, Kim SW, Lee EJ. A weekly administered sustained-release growth hormone reduces visceral fat and waist circumference in abdominal obesity. Horm Metab Res. 2011 Dec;43(13):956-61. doi: 10.1055/s-0031-1291246. Epub 2011 Nov 9. PMID: 22072433.
17. Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Huh KB. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res. 1999;51(2):78-84. doi: 10.1159/000023319. PMID: 10352397.
18. Garcia JM, Merriam GR, Kargi AY. Growth Hormone in Aging. [Updated 2019 Oct 7]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279163/.
19. Qin, Y., Tian, Yp. Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats. Lipids Health Dis 9, 78 (2010). https://doi.org/10.1186/1476-511X-9-78.
20. Cui T, Jimenez JJ, Block NL, Badiavas EV, Rodriguez-Menocal L, Vila Granda A, Cai R, Sha W, Zarandi M, Perez R, Schally AV. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways. Oncotarget. 2016 Aug 16;7(33):52661-52672. doi: 10.18632/oncotarget.11024. PMID: 27494841; PMCID: PMC5288139.
21. Demling RH. The role of anabolic hormones for wound healing in catabolic states. J Burns Wounds. 2005;4:e2. Published 2005 Jan 17.
22. Maeda M, Kadota K, Kajihara M, Sano A, Fujioka K. Sustained release of human growth hormone (hGH) from collagen film and evaluation of effect on wound healing in db/db mice. J Control Release. 2001 Dec 13;77(3):261-72. doi: 10.1016/s0168-3659(01)00512-0. PMID: 11733094.
23. Cristóbal L, de Los Reyes N, Ortega MA, et al. Local Growth Hormone Therapy for Pressure Ulcer Healing on a Human Skin Mouse Model. Int J Mol Sci. 2019;20(17):4157. Published 2019 Aug 26. doi:10.3390/ijms20174157.
24. Dioufa N, Schally AV, Chatzistamou I, et al. Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proc Natl Acad Sci U S A. 2010;107(43):18611-18615. doi:10.1073/pnas.1013942107.
25. Baker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012 Nov;69(11):1420-9. doi: 10.1001/archneurol.2012.1970. PMID: 22869065; PMCID: PMC3764914.
26. High WM Jr, Briones-Galang M, Clark JA, et al. Effect of growth hormone replacement therapy on cognition after traumatic brain injury. J Neurotrauma. 2010;27(9):1565-1575. doi:10.1089/neu.2009.1253.